Microkeratome Market to Surpass US$ 1,347.0 Million by 2027 - Coherent Market Insights

Global Microkeratome Market, by Product (Reusable and Disposable), by End User (Hospitals, Ophthalmic Centers, and Others), by Treatment (Retinal Detachment, Diabetic Retinopathy, Epiretinal membrane, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is expected to be valued at US$ 687.9 million in 2020 and is estimated to exhibit a CAGR of 10.1% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

The global microkeratome market seems to be consolidating with acquisition and business closures. For instance, in 2017, Johnson & Johnson acquired Abbott Medical Optics for US$ 4.325 billion in cash. This acquisition consists of ophthalmic products in three vital areas of patient care which include cataract surgery, consumer eye health, and laser refractive surgery. These product lines are now a part of the ACUVUE Brand Contact Lenses business.

Moreover, Schwind Eye-Tech Solutions, a global technology leader in corneal eyesight laser surgery, performed 6 million refractive error treatments by July 2019 in 100 countries. Around 3.1 million treatments were performed with LASIK technology with the help of a microkeratome or a femtosecond laser. Additionally, the company's touchless SmartSurfACE/TransPRK are witnessing a surge in popularity and therefore in high demand all over the world.

Impact analysis of COVID-19

Microkeratomes are not in high demand due to the COVID-19 pandemic. The global market is hugely impacted in a negative way due to this crisis. Ophthalmologists are not seeing any patients affected by COVID-19 disease. Moreover, patients have also stopped visiting hospitals and clinics due to the spread of the virus. The situation is expected to gradually improve post-COVID, as the operations of ophthalmic centers and hospitals resume.

Browse 26 Market Data Tables and 28 Figures spread through 160 Pages and in-depth TOC on Microkeratome Market, By Product (Reusable and Disposable), By End User (Hospitals, Ophthalmic Centers, and Others), By Treatment (Retinal Detachment, Diabetic Retinopathy, Epiretinal membrane, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Forecast to 2027”

To know the latest trends and insights related to Microkeratome Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/microkeratome-market-3965

Key players in the market are focused on expanding their presence in different countries by conducting educational and training programs for patients as well as healthcare professionals. For instance, in July 2019, a Surgical Vision Experience Center was launched by Johnson & Johnson Vision at their institute in Florida, U.S. This center will serve as a laboratory setting and premier physical training space for various experiential educational programs offering in-depth, hands-on training for practicing ophthalmology for ophthalmic surgeons, optometrists, and ophthalmology residents.

Key Takeaways of the Microkeratome Market:

• The microkeratome market is expected to exhibit a CAGR of 1% during the forecast period (2020-2027) owing to collaborations and partnerships among market players.
• Among treatment, the minimally invasive segment is likely to hold the major revenue share by 2027 owing to the rising prevalence of eye disorders, which is expected to boost demand for microkeratomes and drive the growth of the minimally invasive microkeratome. For instance, according to the World Health Organization (WHO), around 2.2 billion people all over the world were suffering from vision impairment or eye disorders in 2019.
• According to the World Health Organization (WHO), uncorrected cataracts and refractive errors are the leading cause of vision impairment. In 2019, around 2.2 billion people were suffering from eye disorders or vision impairment.
• Major players operating in the microkeratome market are Essilor International, Bausch & Lomb Incorporated, Johnson & Johnson Vision Care, CooperVision, Carl Zeiss AG, Hoya Corporation, Alcon, Inc., STAAR Surgical Company, Marvel Medtech, Abbott Medical Optics Inc., Novartis AG, HAAG-Streit Holding AG, Nidek Co., Ltd., Valeant Pharmaceuticals International, Inc., Sonomed Escalon, Topcon Corporation, Gulden Ophthalmics, FCI Ophthalmics, Ziemer Ophthalmic Systems AG, and Glaukos Corporation.